This article was written by

Follow

Analyst’s Disclosure: I/we have a beneficial long position in the shares of GOOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This article was written by

Follow

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The U.S. housing market accelerated in March despite elevated mortgage rates reducing some of the affordability improvement the market had recently seen, according to a new report.

Zillow released its market report for March which found that newly pending home listings increased 4.6% from a year ago in March.

That increased the number of listings to the second-largest monthly total since the end of the pandemic boom in August 2022, which Zillow said was a positive sign for the market as the home shopping season begins in earnest.

The housing market’s uptick occurred despite mortgage rates increasing from 5.98% at the end of February to 6.38% in late March, according to data from Freddie Mac. Excluding taxes and insurance, the typical mortgage payment increased 1.5% from February, which undercut some of the affordability improvements the market had seen.

THESE 10 HOUSING MARKETS GIVE FIRST-TIME BUYERS THE BEST SHOT AT HOMEOWONERSHIP IN 2026

The housing market is showing signs it’s picking up despite mortgage rates rising higher again. (Daniel Acker/Bloomberg via Getty Images)

Zillow found that the monthly mortgage payment on a typical U.S. home was $1,789 in March, given a 20% down payment, after excluding taxes and insurance. While that figure rose on a monthly basis, it was 4.4% lower than last year, according to the report.

There were 1.23 million homes listed for sale in March. Inventory rose 9.5% from February and active inventory was 4.2% higher than it was a year earlier.

The number of new for sale listings totaled 384,854 in March, an increase of 0.1% from a year ago and 35.6% in February.

AMERICA’S 10 MOST EXPENSIVE ZIP CODES REVEALED

Mortgage rates have risen lately, curbing some of the affordability improvements seen earlier this year. (Getty Images)

Newly pending listings – a figure that measures listings which changed from for sale to pending status rather than closed sales – shows 4.6% growth from a year earlier, and a 29.8% increase over February.

A total of 300,398 homes were sold in March, according to a preliminary reading from the Zillow sales count nowcast. That’s up 3.7% from a year ago and 25.2% from February, though those figures will be revised mid-month.

THE US HOUSING MARKETS THAT ARE SEEING THE LARGEST DROPS IN RENT PRICES

The number of homes sold in March was up on both an annual and monthly basis. (David Paul Morris/Bloomberg via Getty Images)

“Buyers and sellers have been navigating uncertainty and market volatility in some form since the onset of the pandemic, and this month’s concern over energy prices is no different,” said Mischa Fisher, chief economist at Zillow. “However, we have persistent signals that the market has turned a corner.”

“Pent-up demand from three years of low sales volume and winter storms in January and February, along with the tailwind from lower mortgage rates earlier in the year, seem to have buoyed the market as home shopping season kicked off. In particular, the rapid acceleration of daily page views per listing we saw in March was a noteworthy improvement over the dormant market of recent years,” Fischer added.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Oracle on Monday announced it hired a new chief financial officer after the software giant moved forward with layoffs last week.

The company announced that Hilary Maxson will serve as the new CFO, joining Oracle from French industrial conglomerate Schneider Electric where she served in the same role. Oracle said her appointment to the rule is effective immediately.

Maxson, 48, will receive an annual base salary of $950,000 and will be eligible for a performance-based bonus with a target of $2.5 million, Oracle said in a regulatory filing.

The move comes on the heels of Oracle reportedly moving forward with a round of layoffs last week, with CNBC reporting the layoffs will affected thousands of workers at the tech company, according to two people familiar with the matter.

ORACLE LAYING OFF THOUSANDS OF WORKERS TO CUT COSTS AMID AI PUSH: REPORT

Oracle has hired a new CFO as the company grapples with a costly AI buildout and restructures its workforce amid reported layoffs. (David Paul Morris/Bloomberg via Getty Images)

Oracle’s most recent 10-K filing noted the company had about 162,000 full-time employees in May 2025.

The company said in a March filing that it expects the total costs associated with its restructuring plan in fiscal year 2026 to be as high as $2.1 billion, most of which would go to employee severance and related expenses.

Oracle has recently ramped up capital spending to build artificial intelligence (AI) data centers as the company looks to incorporate those tools into its business software services. The company has projected $50 billion in capital expenditures for its fiscal year that ends in May, more than double its spending in the previous fiscal year.

HSBC WEIGHS DEEP JOB CUTS AS AI OVERHAUL UNFOLDS: REPORT

The cloud computing company said in February it planned to raise as much as $50 billion this year through a combination of debt and equity sales.

The company’s stock has been volatile over the last year amid the AI buildout, with shares up about 14% in the last year despite declines of 50% in the last six months and 25% year to date amid concerns that AI presents a competitive threat to software providers.

ORACLE EXPECTED TO SLASH THOUSANDS OF JOBS AS MASSIVE AI SPENDING CREATES FINANCIAL CASH CRISIS

Oracle’s stock has been volatile amid its AI buildout. (Getty Images)

Oracle’s move to hire Maxson as CFO will reinstate a position that was eliminated after Safra Catz became the company’s co-CEO and principal financial officer in 2014.

Maxson will report to Oracle co-CEO Clay Magouyrk in her new role and said in a press release announcing her hiring that she is “excited to join at this pivotal moment.” 

GET FOX BUSINESS ON THE GO BY CLICKING HERE

She added that she looks forward to partnering with the company’s leaders to “continue to invest with discipline and to translate this momentum into durable, long-term value for customers and shareholders.”

Reuters contributed to this report.

SAN FRANCISCO — Researchers at the University of California, San Francisco, have reversed key aspects of age-related cognitive decline in older mice by reducing levels of a single protein called FTL1 in the hippocampus, the brain region critical for learning and memory, according to a study that continues to draw attention more than seven months after its publication.

The findings, originally published in the journal Nature Aging in August 2025, identified ferritin light chain 1 (FTL1), an iron-associated protein, as a key driver of brain aging. Levels of FTL1 rise naturally in the hippocampus as mice grow older, correlating with fewer connections between nerve cells, disrupted energy production in neurons and poorer performance on memory tests. When scientists artificially lowered FTL1 in aged mice, synaptic function improved, neural connections increased and cognitive abilities were restored to levels resembling those of much younger animals.

Lead researcher Saul Villeda, PhD, associate director of the UCSF Bakar Aging Research Institute, described the results as more than just slowing decline. “It is truly a reversal of impairments,” Villeda said in the university’s announcement. “It’s much more than merely delaying or preventing symptoms.” The study’s senior author emphasized that targeting FTL1 appeared to rejuvenate the aging brain at a molecular level rather than simply masking symptoms.

In the experiments, older mice showed elevated FTL1 in the hippocampus alongside structural and metabolic changes that impaired learning and memory. Researchers used viral vectors to deliver treatments that either increased or decreased FTL1 expression specifically in neurons. Boosting FTL1 in young mice caused their brains to behave like those of older animals, with reduced synaptic proteins, fewer neurite branches and weaker memory performance. Conversely, reducing FTL1 in aged mice reversed those effects: synaptic-related proteins increased, neurons formed more connections, and the animals performed significantly better on cognitive tests.

FTL1, part of the ferritin complex that stores iron, appears to disrupt mitochondrial energy production and synaptic maintenance when it accumulates with age. The protein’s iron-binding properties may contribute to oxidative stress or altered cellular metabolism in neurons, though the exact mechanisms require further study. Importantly, lowering FTL1 did not appear to harm overall health metrics in the mice, suggesting a potentially targeted approach with a favorable safety profile.

The research team, led by first author L. Remesal and colleagues, combined transcriptomic analysis, mass spectrometry and behavioral testing to pinpoint FTL1 as the standout protein consistently elevated in the aging hippocampus across datasets. While many proteins change with age, FTL1 stood out for its strong correlation with cognitive impairment. The study received support from the National Institutes of Health and other funding sources focused on aging biology.

Experts not involved in the work hailed the findings as a significant step in understanding brain aging. The hippocampus is particularly vulnerable in humans as well, showing early signs of decline linked to normal aging and diseases such as Alzheimer’s. If similar mechanisms operate in people, targeting FTL1 or related pathways could one day lead to therapies that preserve or restore memory function in older adults.

As of April 6, 2026, no human trials have been announced, and researchers caution that mouse results do not always translate directly to people. Developing safe, brain-penetrating drugs or gene therapies to modulate FTL1 remains a major challenge. Iron regulation is delicate, and systemic changes could carry risks, though the study’s neuron-specific targeting offers a promising model for precision approaches.

The UCSF discovery fits into a broader wave of research seeking “rejuvenation” factors in aging. Previous studies have explored young blood factors, senolytic drugs and reprogramming techniques, but identifying a single actionable protein like FTL1 simplifies the path toward intervention. Villeda’s lab has long investigated how systemic factors influence brain aging, and this work highlights a cell-intrinsic driver within neurons themselves.

Public interest in the study surged upon its release and received renewed attention in early April 2026 through science news roundups highlighting its potential implications for cognitive health. Social media discussions have ranged from cautious optimism about future treatments to broader questions about extending healthy brain function into later life.

While the findings are exciting, scientists stress the need for replication and deeper mechanistic studies. Questions remain about how long the cognitive benefits last after FTL1 reduction, whether the intervention affects other aspects of aging or health span, and how FTL1 interacts with known risk factors for dementia such as inflammation, vascular changes or protein aggregates like amyloid and tau.

The study also opens avenues for exploring FTL1 in human brain tissue from aged donors or patients with mild cognitive impairment. If elevated FTL1 proves consistent in humans, it could serve as a biomarker or therapeutic target. Existing drugs that influence iron metabolism or ferritin levels might offer starting points, though new compounds specifically aimed at neuronal FTL1 would likely be required.

UCSF researchers continue to investigate related pathways, including how FTL1 affects energy metabolism and whether partial rather than complete reduction could yield benefits with minimal side effects. The team is also examining interactions with other aging hallmarks, such as mitochondrial dysfunction and proteostasis.

For now, lifestyle factors known to support brain health — regular exercise, cognitive engagement, healthy diet and good sleep — remain the most evidence-based recommendations for preserving memory. The FTL1 discovery, however, adds a molecular target that could complement those approaches in the future.

The research underscores the rapid progress in aging biology, where interventions once considered science fiction are moving closer to clinical reality. If successful in humans, therapies based on lowering FTL1 or blocking its effects could help millions facing age-related cognitive decline, from mild forgetfulness to more severe impairment.

As the scientific community digests and builds upon the August 2025 paper, UCSF’s work stands as a compelling example of how targeting a single protein can produce dramatic rejuvenation in an aging brain. While human applications remain years away, the study injects fresh hope into the quest for healthier cognitive aging.

Experts predict increased funding and collaboration around iron-related proteins in neurodegeneration. The findings may also influence research into other age-related conditions where iron dysregulation plays a role.

In the meantime, the mice in Villeda’s lab that had their memory restored continue to serve as living proof that some aspects of brain aging may not be as inevitable as once thought. For an aging global population, that message carries profound implications.